Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso.
Antiretroviral therapy
Burkina Faso
Female sex workers
HIV-1
Immunovirological discordance
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
03 Feb 2022
03 Feb 2022
Historique:
received:
19
09
2021
accepted:
31
01
2022
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
In people living with HIV/AIDS (PLWHA), initiation of antiretroviral therapy (ART) leads to sustained effective suppression of viral replication and increasing CD4 + T cell count. However, a fraction of ART-treated patients still fail to reach adequate CD4 + T cell number despite a suppressed viral load (VL), and this phenomenon is defined as immunovirological discordance (IVD). In Africa, several studies have reported immunovirological outcomes of antiretroviral therapy, but little is known about IVD occurrence in Female sex workers (FSW). This study aimed to assess the prevalence of IVD and associated factors among a cohort of HIV infected FSW in Burkina Faso. We conducted a cohort study from December 2003 to October 2016. Immunovirological discordance was defined as CD4 + T cell gain < 100 cells/µL despite a suppressed VL (VL < 1000 copies/mL) 12 months after ART initiation. The CD4 + T cells were counted using BD FACSCount™ System and point of care Pima™ CD4 + Analyzer. HIV-1 RNA was quantified by real-time polymerase-chain-reaction assay with the use of the ABI 7000 system. We conducted a logistic regression to identify factors associated with discordant responses. Among the 123 HIV-1 infected FSW having at least 12 months follow-up on ART, 105 (85.4%) achieved HIV-1 RNA suppression. Among the latter 25 gained less than 100 CD4 + T cells within 12 months follow-up. The IVD rate was 23.8% (95%CI 16.04%-33.11%). After adjustment for age, WHO clinical stage and ART regimen including nucleoside/nucleotide reverse transcriptase inhibitors, only baseline CD4 + T cell count between 200 to 350 cells/µL (adjusted OR: 4.15; 95%CI 1.13-15.22) and 350 to 500 cells/µL (adjusted OR: 17.50; 95%CI 2.68-114.31) remain significantly associated with IVD occurrence. Immunovirological discordance response was common in FSW with proportions close to those observed in the general population. A diagnosis and personalized follow-up of patients who do not achieve full immune reconstitution would make it possible to avoid complications in terms of morbidity and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
In people living with HIV/AIDS (PLWHA), initiation of antiretroviral therapy (ART) leads to sustained effective suppression of viral replication and increasing CD4 + T cell count. However, a fraction of ART-treated patients still fail to reach adequate CD4 + T cell number despite a suppressed viral load (VL), and this phenomenon is defined as immunovirological discordance (IVD). In Africa, several studies have reported immunovirological outcomes of antiretroviral therapy, but little is known about IVD occurrence in Female sex workers (FSW). This study aimed to assess the prevalence of IVD and associated factors among a cohort of HIV infected FSW in Burkina Faso.
METHODS
METHODS
We conducted a cohort study from December 2003 to October 2016. Immunovirological discordance was defined as CD4 + T cell gain < 100 cells/µL despite a suppressed VL (VL < 1000 copies/mL) 12 months after ART initiation. The CD4 + T cells were counted using BD FACSCount™ System and point of care Pima™ CD4 + Analyzer. HIV-1 RNA was quantified by real-time polymerase-chain-reaction assay with the use of the ABI 7000 system. We conducted a logistic regression to identify factors associated with discordant responses.
RESULTS
RESULTS
Among the 123 HIV-1 infected FSW having at least 12 months follow-up on ART, 105 (85.4%) achieved HIV-1 RNA suppression. Among the latter 25 gained less than 100 CD4 + T cells within 12 months follow-up. The IVD rate was 23.8% (95%CI 16.04%-33.11%). After adjustment for age, WHO clinical stage and ART regimen including nucleoside/nucleotide reverse transcriptase inhibitors, only baseline CD4 + T cell count between 200 to 350 cells/µL (adjusted OR: 4.15; 95%CI 1.13-15.22) and 350 to 500 cells/µL (adjusted OR: 17.50; 95%CI 2.68-114.31) remain significantly associated with IVD occurrence.
CONCLUSIONS
CONCLUSIONS
Immunovirological discordance response was common in FSW with proportions close to those observed in the general population. A diagnosis and personalized follow-up of patients who do not achieve full immune reconstitution would make it possible to avoid complications in terms of morbidity and mortality.
Identifiants
pubmed: 35114959
doi: 10.1186/s12879-022-07109-8
pii: 10.1186/s12879-022-07109-8
pmc: PMC8812047
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2020 Jan 6;15(1):e0227124
pubmed: 31905222
HIV Med. 2010 Feb;11(2):152-60
pubmed: 19732175
AIDS. 2013 Sep 10;27(14):2225-32
pubmed: 23660577
AIDS. 2007 May 11;21(8):939-46
pubmed: 17457087
Mali Med. 2015;30(4):58-64
pubmed: 29927136
Clin Infect Dis. 2013 May;56(9):1340-3
pubmed: 23315315
J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):e98-107
pubmed: 24853304
Lancet. 2004 Jul 3-9;364(9428):51-62
pubmed: 15234856
AIDS Res Ther. 2008 Oct 28;5:23
pubmed: 18957083
BMC Public Health. 2020 May 15;20(1):697
pubmed: 32414352
AIDS. 2002 Feb 15;16(3):359-67
pubmed: 11834947
Int J STD AIDS. 2001 Sep;12(9):573-81
pubmed: 11516366
J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):517-21
pubmed: 11981369
AIDS. 2013 Nov 13;27(17):2759-63
pubmed: 23842127
Clin Infect Dis. 2005 Aug 1;41(3):361-72
pubmed: 16007534
Sex Transm Dis. 2011 Apr;38(4):316-23
pubmed: 23330152
Open AIDS J. 2012;6:16-25
pubmed: 22435082
Rev Med Virol. 2017 Jan;27(1):
pubmed: 27714898
Clin Infect Dis. 2007 Feb 1;44(3):441-6
pubmed: 17205456
PLoS One. 2016 Jun 10;11(6):e0156099
pubmed: 27284683
AIDS Rev. 2006 Apr-Jun;8(2):88-97
pubmed: 16848276
N Engl J Med. 2006 Jan 19;354(3):251-60
pubmed: 16421366
J Clin Virol. 2014 Sep;61(1):20-33
pubmed: 24973812
J Acquir Immune Defic Syndr. 2007 May 1;45(1):52-9
pubmed: 17460471
J Infect Dis. 2001 May 1;183(9):1328-35
pubmed: 11294663
J Infect Dis. 2001 Apr 15;183(8):1290-4
pubmed: 11262215
Pan Afr Med J. 2017 May 08;27:16
pubmed: 28748017
AIDS. 2001 Sep 28;15(14):1749-56
pubmed: 11579235
BMC Infect Dis. 2013 Mar 01;13:113
pubmed: 23452915
Expert Rev Clin Immunol. 2013 Nov;9(11):1135-49
pubmed: 24168417
J Leukoc Biol. 2020 Apr;107(4):597-612
pubmed: 31965635
PLoS One. 2016 Jul 20;11(7):e0159446
pubmed: 27438000
J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):307-13
pubmed: 19194311
J Clin Virol. 2018 May;102:7-11
pubmed: 29454196
Lancet Infect Dis. 2006 May;6(5):280-7
pubmed: 16631548
BMC Infect Dis. 2021 Jun 12;21(1):561
pubmed: 34118891
J Clin Microbiol. 2005 Jun;43(6):2709-17
pubmed: 15956387
Blood. 1999 Aug 1;94(3):1021-7
pubmed: 10419894
J Infect Dis. 2003 May 15;187(10):1534-43
pubmed: 12721933
J Infect Dis. 2016 Jul 15;214(2):216-25
pubmed: 27073222
AIDS. 2018 May 15;32(8):1043-1051
pubmed: 29547445
Afr J AIDS Res. 2016 Dec;15(4):377-386
pubmed: 27974017
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93
pubmed: 16249702
Patient Prefer Adherence. 2012;6:227-37
pubmed: 22536059
AIDS. 2011 Sep 24;25(15):1813-22
pubmed: 21412126
BMC Public Health. 2011 Sep 14;11:700
pubmed: 21917177
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):454-8
pubmed: 16010169
PLoS One. 2014 Feb 12;9(2):e88552
pubmed: 24533106
Clin Dev Immunol. 2012;2012:670957
pubmed: 22474480